脑梗死患者应用阿托伐他汀联合甲钴胺对临床疗效影响的分析

Analysis of cerebral infarction patients with Atorvastatin combined with Mecobalamin on clinical effects

目的探析脑梗死患者应用阿托伐他汀联合甲钴胺对临床效果、C反应蛋白(CRP)及血脂指标的影响。方法选取我院2015年1月—2017年8月接收的102例脑梗死患者资料加以探究,由于医治药物不同可分成两组,行甲钴胺联合阿托伐他汀医治的51例患者设研究组,行阿托伐他汀医治的51例患者设对照组,比对两组血脂指标、C反应蛋白及NIHSS、ADL评分。结果研究组各项血脂指标水平较对照组低,比较差异显著具统计意义(P<0.05);且研究组医治后NIHSS、ADL评分及C反应蛋白比对照组优,比较差异显著具统计意义(P<0.05)。结论脑梗死患者行甲钴胺联合阿托伐他汀医治可改善神经功能缺损,提高生存质量,降低C反应蛋白与血脂指标水平。

Objective:To explore the effect of atorvastatin combined with methylamine on clinical effect,c-reactive protein(CRP)and blood lipid index in patients with cerebral infarction.Methods:Select our hospital in January 2015 August 2017 to receive the data of 102 cases of cerebral infarction patients to explore,due to different treatment drugs can be divided into two groups,line a cobalt amine joint atorvastatin treatment of 51 patients with a team,and line of atorvastatin treatment of 51 patients were set in the control group,compare two groups of blood fat index,CRP and NIHSS,ADL scores.Results:The indexes of blood lipid in the study group were lower than the control group,and the difference was statistically significant(P<0.05).In the study,the NIHSS,ADL score and c-reactive protein were better than the control group,and the difference was statistically significant(P<0.05).Conclusion:Patients with cerebral infarction combined with atorvastatin can improve the neurological deficit,improve the quality of life,and reduce the level of c-reactive protein and blood lipid.